Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 9
2016 9
2017 6
2018 8
2019 8
2020 15
2021 11
2022 15
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Complications Of Image-Guided Drainage.
Meetschen M, Bücker A, Nikolaou K, Salhöfer L, Zensen S, Schaarschmidt BM, Wetter A, Haubold J. Meetschen M, et al. Among authors: schaarschmidt bm. Dtsch Arztebl Int. 2023 Aug 21;120(33-34):553-554. doi: 10.3238/arztebl.m2023.0140. Dtsch Arztebl Int. 2023. PMID: 37732592 Free PMC article. No abstract available.
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.
Kessler L, Hirmas N, Pabst KM, Hamacher R, Ferdinandus J, Schaarschmidt BM, Milosevic A, Nader M, Umutlu L, Uhl W, Reinacher-Schick A, Lugnier C, Witte D, Niedergethmann M, Herrmann K, Fendler WP, Siveke JT. Kessler L, et al. Among authors: schaarschmidt bm. J Nucl Med. 2023 Dec 1;64(12):1910-1917. doi: 10.2967/jnumed.122.264827. J Nucl Med. 2023. PMID: 37973185
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study.
Mei R, Kessler L, Pabst KM, Weber M, Schmidkonz C, Rischpler C, Zacho HD, Hope T, Schwarzenböck SM, Allen-Auerbach M, Emmett L, Ferdinandus J, Unterrainer M, Schaarschmidt BM, Umutlu L, Farolfi A, Castellucci P, Nanni C, Telo S, Fanti S, Herrmann K, Fendler WP. Mei R, et al. Among authors: schaarschmidt bm. J Nucl Med. 2023 Jul;64(7):1043-1048. doi: 10.2967/jnumed.122.265245. Epub 2023 May 25. J Nucl Med. 2023. PMID: 37230530
Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma.
Pabst KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, Steiger K, Bartel T, Schaarschmidt BM, Milosevic A, Seifert R, Nader M, Kessler L, Siveke JT, Lueckerath K, Kasper S, Herrmann K, Hirmas N, Schmidt HH, Hamacher R, Fendler WP. Pabst KM, et al. Among authors: schaarschmidt bm. J Nucl Med. 2023 Jul;64(7):1049-1055. doi: 10.2967/jnumed.122.265215. Epub 2023 Apr 6. J Nucl Med. 2023. PMID: 37024301 Free PMC article.
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.
Hamacher R, Pabst KM, Cheung PF, Heilig CE, Hüllein J, Liffers ST, Borchert S, Costa PF, Schaarschmidt BM, Kessler L, Miera MA, Droste M, Akbulut M, Falkenhorst J, Zarrad F, Kostbade K, Mavroeidi IA, Glimm H, Umutlu L, Schuler M, Hübschmann D, Bauer S, Fröhling S, Herrmann K, Siveke JT, Schildhaus HU, Fendler WP. Hamacher R, et al. Among authors: schaarschmidt bm. J Nucl Med. 2024 Feb 1;65(2):252-257. doi: 10.2967/jnumed.123.266411. J Nucl Med. 2024. PMID: 38176718
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT.
Weber M, Pettersson O, Seifert R, Schaarschmidt BM, Fendler WP, Rischpler C, Lahner H, Herrmann K, Sundin A. Weber M, et al. Among authors: schaarschmidt bm. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):841-851. doi: 10.1007/s00259-023-06502-y. Epub 2023 Nov 10. Eur J Nucl Med Mol Imaging. 2024. PMID: 37947848 Free PMC article.
87 results